The latest from Strata Oncology

IASLC23

Immunotherapy Response Score (IRS) Predicts Pembrolizumab Clinical Benefit in Patients with NSCLC in TPS≥50%

AACR 2023

Validation of an Integrative Pan-solid Tumor Predictor of Pembrolizumab Monotherapy Benefit

AACR 2023

Strata PATH™: A Multicohort, Non-randomized, Open-label Phase 2 Trial to Explore Efficacy and Safety of FDA-Approved Cancer Therapies in Novel Biomarker-guided Patient Population

AACR 2023

A Multivariate Biomarker Predicts Sacituzumab Govitecan (SG) Response in Solid Tumors

AACR 2023

Evaluation of HER2 RNA Expression as a Potential Predictive Biomarker for Anti-HER2 Therapy